<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03079921</url>
  </required_header>
  <id_info>
    <org_study_id>826386</org_study_id>
    <secondary_id>2R01DK091331-06</secondary_id>
    <nct_id>NCT03079921</nct_id>
  </id_info>
  <brief_title>Adrenergic System in Islet Transplantation</brief_title>
  <official_title>Adrenergic Contribution to Glucose Counterregulation in Islet Transplantation</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institutes of Health (NIH)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
    <collaborator>
      <agency>National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine the effect of sympathetic neural and hormonal (epinephrine) input on islet cell&#xD;
      hormonal responses to insulin-induced hypoglycemia in type 1 diabetic recipients of&#xD;
      intrahepatic islet transplantation. We hypothesize that α-adrenergic (neural) blockage will&#xD;
      abolish insulin-mediated suppression of C-peptide, attenuating α-cell glucagon secretion&#xD;
      during hypoglycemia, and that β-adrenergic (hormonal) blockage will have no effect. Glucose&#xD;
      counterregulatory responses will be measured during hyperinsulinemic euglycemic-hypoglycemic&#xD;
      clamps on three occasions with randomized, double-blind administration of the α-adrenergic&#xD;
      blocker phentolamine, the β-adrenergic blocker propranolol, or placebo. The demonstration of&#xD;
      neural rather than hormonal regulation of the transplanted islet cell response to&#xD;
      hypoglycemia is critical for understanding the mechanism for protection from hypoglycemia&#xD;
      afforded by intrahepatically transplanted.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is designed to test the hypothesis that α-adrenergic (neural) blockade will&#xD;
      abolish insulin-mediated suppression of C-peptide, attenuating α-cell glucagon secretion&#xD;
      during hypoglycemia, and that β-adrenergic (hormonal) blockade will have no effect. Glucose&#xD;
      counterregulatory responses will be measured during hyperinsulinemic euglycemic-hypoglycemic&#xD;
      clamps on three occasions with randomized, double-blind administration of the α-adrenergic&#xD;
      blocker phentolamine, the β-adrenergic blocker propranolol, or placebo. The demonstration of&#xD;
      neural rather than hormonal regulation of the transplanted islet cell response to&#xD;
      hypoglycemia is critical for understanding the mechanism for protection from hypoglycemia&#xD;
      afforded by intrahepatically transplanted islets.&#xD;
&#xD;
      Glucose counterregulation has not been studied in type 1 diabetic recipients of extrahepatic&#xD;
      islet transplantation. Comparison of glucose counterregulatory responses measured during&#xD;
      hyperinsulinemic euglycemic-hypoglycemic clamps will be compared to those obtained from type&#xD;
      1 diabetic recipients of intrahepatic islet transplantation studied under the placebo&#xD;
      condition above.&#xD;
&#xD;
      Glucose counterregulation has not been directly compared between recipients of intrahepatic&#xD;
      auto- and allo-islet transplantation. Direct comparison of glucose counterregulatory&#xD;
      responses under the same experimental conditions is required to understand whether mechanisms&#xD;
      other than the glucagon response may be important to the reported hypoglycemia affecting&#xD;
      pancreatectomized recipients of islet auto-transplantation.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">January 20, 2017</start_date>
  <completion_date type="Anticipated">December 2023</completion_date>
  <primary_completion_date type="Anticipated">December 2022</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <intervention_model_description>This study is a within subject and across group mechanistic design.&#xD;
Islet cell hormonal responses to a hyperinsulinemic euglycemic-hypoglycemic clamp will be assessed in &quot;Group 1&quot; on three occasions with randomized, double-blind administration of the α-adrenergic blocker phentolamine, the β-adrenergic blocker propranolol, or placebo.&#xD;
Responses in &quot;Group 1&quot; under the placebo condition will be used for comparison to those obtained from hyperinsulinemic euglycemic-hypoglycemic clamp testing on one occasion in subjects in each of &quot;Group 2&quot; and &quot;Group 3&quot;.</intervention_model_description>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
    <masking_description>Conditions of testing for &quot;Group 1&quot; (intra-hepatic islet recipients) will remain double-blind for each subject until their completion of all testing visits, unless for safety concerns, either the PI or Medical Monitor request an unblinding. Groups &quot;2&quot; and &quot;3&quot; will have no masking.</masking_description>
  </study_design_info>
  <primary_outcome>
    <measure>C-PEPTIDE suppression during hyperinsulinemia euglycemia.</measure>
    <time_frame>For C-peptide at the 60-90 time-point during the hyperinsulinemic euglycemic-hypoglycemic clamp.</time_frame>
    <description>The primary outcome measures will be the levels of C-peptide during hyperinsulinemia euglycemia.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>GLUCAGON activation during hyperinsulinemia hypoglycemia.</measure>
    <time_frame>For Glucagon at the 150-180 minute time-point during the hyperinsulinemic euglycemic-hypoglycemic clamp.</time_frame>
    <description>The primary outcome measures will be the levels of glucagon during hyperinsulinemia hypoglycemia.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EPINEPHRINE during hyperinsulinemia hypoglycemia.</measure>
    <time_frame>During metabolic testing in the 150-180 minute time-point of the hyperinsulinemic euglycemic-hypoglycemic clamp.</time_frame>
    <description>Secondary outcome measures will include levels of epinephrine during hyperinsulinemia hypoglycemia.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rates of ENDOGENOUS GLUCOSE PRODUCTION during hyperinsulinemia hypoglycemia.</measure>
    <time_frame>During metabolic testing in the 150-180 minute time-point of the hyperinsulinemic euglycemic-hypoglycemic clamp.</time_frame>
    <description>Secondary outcome measures will include rates of endogenous glucose production during hyperinsulinemia hypoglycemia</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>AUTONOMIC SYMPTOMS during hyperinsulinemia</measure>
    <time_frame>During metabolic testing; this symptom questionnaire will be asked at the following time points: -15min, -1min, 30min, 60min,75min, 90min,120min, 150min, 165min, 180min.</time_frame>
    <description>Secondary outcome measures will include levels of autonomic symptoms during hyperinsulinemia hypoglycemia. Autonomic symptoms will be measured by answering a short symptoms questionnaire with a level scale of 0-5.</description>
  </secondary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">11</enrollment>
  <condition>Type1diabetes</condition>
  <condition>Hypoglycemia</condition>
  <condition>Hypoglycemia Unawareness</condition>
  <condition>Islet Cell Transplantation</condition>
  <arm_group>
    <arm_group_label>Group 1-Propranolol Intra-hepatic islet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dose of propranolol will be 0.48 μg/kilogram•minute, which will provide a total dose of 0.10 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1-Phentolamine Intra-hepatic islet</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>The dose of phentolamine will be 0.95 μg/kg•min, which will provide a total dose of 0.20 mg/kg. It will be administered 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 1- Placebo Intra-hepatic islet</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Placebo in 100mL NSS. Infuse Intravenously at 0.0095 ML/KG/MIN. 1 x only via intravenous infusion over 3.5 hours, starting 30 min before conduct of a hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 2 - Extra-hepatic islet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Group 3 - Intra-hepatic auto islet</arm_group_label>
    <arm_group_type>No Intervention</arm_group_type>
    <description>Hyperinsulinemic euglycemic (90 min) followed by hypoglycemia (90 min) clamp only.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Phentolamine</intervention_name>
    <description>Physiologic receptor blockade (α1-receptor).</description>
    <arm_group_label>Group 1-Phentolamine Intra-hepatic islet</arm_group_label>
    <other_name>Regitine</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Propranolol</intervention_name>
    <description>Physiologic receptor blockade (β2-receptor).</description>
    <arm_group_label>Group 1-Propranolol Intra-hepatic islet</arm_group_label>
    <other_name>Inderal</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>100mL bag of Normal Saline Solution (NSS).</description>
    <arm_group_label>Group 1- Placebo Intra-hepatic islet</arm_group_label>
    <other_name>Saline</other_name>
    <other_name>Sodium Chloride Solution</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
        GROUP 1&#xD;
&#xD;
          1. Male and female subjects age 21 to 65 years of age.&#xD;
&#xD;
          2. Subjects who are able to provide written informed consent and to comply with the&#xD;
             procedures of the study protocol.&#xD;
&#xD;
          3. Clinical history compatible with type 1 diabetes with onset of disease at &lt; 40 years&#xD;
             of age and insulin-dependent for &gt; 10 years at the time of islet transplantation &gt; 6&#xD;
             months before study.&#xD;
&#xD;
          4. Stable islet graft function defined by C-peptide &gt; 0.5 ng/ml and insulin-independent&#xD;
             or insulin-dependent with daily insulin requirement &lt; 0.2 units/kg•d to maintain HbA1c&#xD;
             &lt; 7.0%.&#xD;
&#xD;
          5. Use of standard immunosuppression consisting of tacrolimus with or without sirolimus&#xD;
             or mycophenolic acid. Substitutions of tacrolimus with cyclosporine, and of sirolimus&#xD;
             or mycophenolic acid with azathioprine are permissible if stable for over 3 months.&#xD;
             Prednisone is allowable if no more than 5 mg daily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        GROUP 1&#xD;
&#xD;
          1. BMI ≥ 30 kg/m2.&#xD;
&#xD;
          2. Insulin requirement of ≥ 0.2 units/kg•day.&#xD;
&#xD;
          3. HbA1c ≥ 7.0%.&#xD;
&#xD;
          4. Uncontrolled hypertension: systolic blood pressure &gt; 160 mmHg or diastolic blood&#xD;
             pressure &gt; 100 mmHg.&#xD;
&#xD;
          5. History of cardiovascular disease, including coronary artery, cerebrovascular or&#xD;
             peripheral vascular disease, or current use of β-blocker therapy.&#xD;
&#xD;
          6. Bronchial asthma.&#xD;
&#xD;
          7. Abnormal kidney function: Estimated glomerular filtration rate (eGFR) &lt; 60 ml/min/1.73&#xD;
             m2.&#xD;
&#xD;
          8. Abnormal liver function: persistent elevation of liver function tests &gt; 1.5 times the&#xD;
             upper limit of normal.&#xD;
&#xD;
          9. Untreated hypothyroidism, Addison's disease, or Celiac disease.&#xD;
&#xD;
         10. Anemia: baseline hemoglobin concentration &lt; 11 g/dl in women and &lt; 12 g/dl in men.&#xD;
&#xD;
         11. Presence of a seizure disorder not related to prior severe hypoglycemia.&#xD;
&#xD;
         12. Use of glucocorticoids greater than 5 mg of prednisone daily, or an equivalent&#xD;
             physiologic dose of hydrocortisone.&#xD;
&#xD;
         13. For female participants of child-bearing potential: Positive pregnancy test, presently&#xD;
             breast-feeding, or unwillingness to use effective contraceptive measures for the&#xD;
             duration of study participation. Oral contraceptives, intra-uterine devices,&#xD;
             Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable&#xD;
             contraceptive methods; condoms used alone are not acceptable.&#xD;
&#xD;
         14. Treatment with any anti-diabetic medication other than insulin within 4 weeks of&#xD;
             enrollment.&#xD;
&#xD;
         15. Use of any investigational agents within 4 weeks of enrollment.&#xD;
&#xD;
         16. Any medical condition that, in the opinion of the PI, will interfere with the safe&#xD;
             completion of the study&#xD;
&#xD;
        Inclusion Criteria GROUP 2&#xD;
&#xD;
          1. Male and female subjects age 21 to 65 years of age.&#xD;
&#xD;
          2. Subjects who are able to provide written informed consent and to comply with the&#xD;
             procedures of the study protocol.&#xD;
&#xD;
          3. Clinical history compatible with type 1 diabetes with onset of disease at &lt; 40 years&#xD;
             of age and insulin-dependent for &gt; 10 years at the time of islet transplantation &gt; 6&#xD;
             months before study.&#xD;
&#xD;
          4. Stable islet graft function defined by C-peptide &gt; 0.5 ng/ml and insulin-independent&#xD;
             or insulin-dependent with daily insulin requirement &lt; 0.2 units/kg•d to maintain HbA1c&#xD;
             &lt; 7.0%.&#xD;
&#xD;
          5. Use of standard immunosuppression consisting of tacrolimus with or without sirolimus&#xD;
             or mycophenolic acid. Substitutions of tacrolimus with cyclosporine, and of sirolimus&#xD;
             or mycophenolic acid with azathioprine are permissible if stable for over 3 months.&#xD;
             Prednisone is allowable if no more than 5 mg daily.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        GROUP 2&#xD;
&#xD;
          1. BMI ≥ 30 kg/m2.&#xD;
&#xD;
          2. Insulin requirement of ≥ 0.2 units/kg•day.&#xD;
&#xD;
          3. HbA1c ≥ 7.0%.&#xD;
&#xD;
          4. Uncontrolled hypertension: systolic blood pressure &gt; 160 mmHg or diastolic blood&#xD;
             pressure &gt; 100 mmHg.&#xD;
&#xD;
          5. Active cardiovascular disease, including coronary artery, cerebrovascular or&#xD;
             peripheral vascular disease.&#xD;
&#xD;
          6. Abnormal kidney function: eGFR &lt; 60 ml/min/1.73 m2.&#xD;
&#xD;
          7. Abnormal liver function: persistent elevation of liver function tests &gt; 1.5 times the&#xD;
             upper limit of normal.&#xD;
&#xD;
          8. Untreated hypothyroidism, Addison's disease, or Celiac disease.&#xD;
&#xD;
          9. Anemia: baseline hemoglobin concentration &lt; 11 g/dl in women and &lt; 12 g/dl in men.&#xD;
&#xD;
         10. Presence of a seizure disorder not related to prior severe hypoglycemia.&#xD;
&#xD;
         11. Use of glucocorticoids greater than 5 mg of prednisone daily, or an equivalent&#xD;
             physiologic dose of hydrocortisone.&#xD;
&#xD;
         12. For female participants of child-bearing potential: Positive pregnancy test, presently&#xD;
             breast-feeding, or unwillingness to use effective contraceptive measures for the&#xD;
             duration of study participation. Oral contraceptives, intra-uterine devices,&#xD;
             Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable&#xD;
             contraceptive methods; condoms used alone are not acceptable.&#xD;
&#xD;
         13. Treatment with any anti-diabetic medication other than insulin within 4 weeks of&#xD;
             enrollment.&#xD;
&#xD;
         14. Use of any investigational agents within 4 weeks of enrollment.&#xD;
&#xD;
         15. Any medical condition that, in the opinion of the PI, will interfere with the safe&#xD;
             completion of the study&#xD;
&#xD;
        Inclusion Criteria GROUP 3&#xD;
&#xD;
        Patients who meet all of the following criteria are eligible for participation in Group 3&#xD;
        of this study:&#xD;
&#xD;
          1. Male and female subjects age 21 to 65 years of age.&#xD;
&#xD;
          2. Subjects who are able to provide written informed consent and to comply with the&#xD;
             procedures of the study protocol.&#xD;
&#xD;
          3. Clinical history compatible with total pancreatectomy and autologous islet&#xD;
             transplantation &gt; 6 months before study.&#xD;
&#xD;
          4. Stable islet graft function defined by C-peptide &gt; 0.5 ng/ml and insulin-independent&#xD;
             or insulin-dependent with daily insulin requirement &lt; 0.2 units/kg•d to maintain HbA1c&#xD;
             &lt; 7.0%.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
        GROUP 3&#xD;
&#xD;
          1. BMI ≥ 30 kg/m2.&#xD;
&#xD;
          2. Insulin requirement of ≥ 0.2 units/kg•day.&#xD;
&#xD;
          3. HbA1c ≥ 7.0%.&#xD;
&#xD;
          4. Uncontrolled hypertension: systolic blood pressure &gt; 160 mmHg or diastolic blood&#xD;
             pressure &gt; 100 mmHg.&#xD;
&#xD;
          5. Active cardiovascular disease, including coronary artery, cerebrovascular or&#xD;
             peripheral vascular disease.&#xD;
&#xD;
          6. Abnormal kidney function: eGFR &lt; 60 ml/min/1.73 m2.&#xD;
&#xD;
          7. Abnormal liver function: persistent elevation of liver function tests &gt; 1.5 times the&#xD;
             upper limit of normal.&#xD;
&#xD;
          8. Anemia: baseline hemoglobin concentration &lt; 11 g/dl in women and &lt; 12 g/dl in men.&#xD;
&#xD;
          9. Presence of a seizure disorder not related to prior severe hypoglycemia.&#xD;
&#xD;
         10. Use of glucocorticoids greater than 5 mg of prednisone daily, or an equivalent&#xD;
             physiologic dose of hydrocortisone.&#xD;
&#xD;
         11. For female participants of child-bearing potential: Positive pregnancy test, presently&#xD;
             breast-feeding, or unwillingness to use effective contraceptive measures for the&#xD;
             duration of study participation. Oral contraceptives, intra-uterine devices,&#xD;
             Norplant®, Depo-Provera®, and barrier devices with spermicide are acceptable&#xD;
             contraceptive methods; condoms used alone are not acceptable.&#xD;
&#xD;
         12. Treatment with any anti-diabetic medication other than insulin within 4 weeks of&#xD;
             enrollment.&#xD;
&#xD;
         13. Use of any investigational agents within 4 weeks of enrollment.&#xD;
&#xD;
         14. Any medical condition that, in the opinion of the PI, will interfere with the safe&#xD;
             completion of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Male or Female at birth.</gender_description>
    <minimum_age>21 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Michael R Rickels, MD., MS</last_name>
    <role>Principal Investigator</role>
    <affiliation>Division of Endocrinology, Diabetes &amp; Metabolism, Perelman School of Medicine</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania - Institute for Diabetes, Obesity and Metabolism</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.med.upenn.edu/apps/faculty/index.php/p32032</url>
    <description>Perelman School of Medicine / Faculty Search /Michael Rickels, M.D., M.S.</description>
  </link>
  <link>
    <url>https://clinicalresearch.itmat.upenn.edu/?_ga=1.86091032.1687586810.1437483178</url>
    <description>Research Studies at the University of Pennsylvania</description>
  </link>
  <link>
    <url>https://www.med.upenn.edu/idom/trials.html</url>
    <description>Institute for Diabetes, Obesity and Metabolism Research Studies</description>
  </link>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>February 28, 2017</study_first_submitted>
  <study_first_submitted_qc>March 8, 2017</study_first_submitted_qc>
  <study_first_posted type="Actual">March 15, 2017</study_first_posted>
  <last_update_submitted>February 22, 2021</last_update_submitted>
  <last_update_submitted_qc>February 22, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 24, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Michael R. Rickels, MD, MS</investigator_full_name>
    <investigator_title>Michael R. Rickels, M.D., M.S. Associate Professor of Medicine Division of Endocrinology, Diabetes &amp; Metabolism Director, Translational Research Program Institute for Diabetes, Obesity &amp; Metabolism University of Pennsylvania Perelman School of Medicine</investigator_title>
  </responsible_party>
  <keyword>Islet Graft Function</keyword>
  <keyword>Islet Cell transplantation</keyword>
  <keyword>Auto-islet transplantation</keyword>
  <keyword>Intra-hepatic islets</keyword>
  <keyword>Extra-hepatic islets</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypoglycemia</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Propranolol</mesh_term>
    <mesh_term>Phentolamine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
    <ipd_description>It is not yet known if there will be any further plan to make IPD available besides the Informed Consent.</ipd_description>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

